Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 572M 510M 471M 428M 801M 54.28B 813M 5.67B 2.24B 28.41B 2.15B 2.1B 89.66B P/E 2026 *
2.83x
P/E 2027 * 2.63x
Enterprise Value 572M 510M 471M 428M 801M 54.28B 813M 5.67B 2.24B 28.41B 2.15B 2.1B 89.66B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.16x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day-3.08%
1 week-1.14%
Current month-12.85%
1 month-18.97%
3 months-8.71%
6 months-8.71%
Current year+2.67%
1 week 3.38
Extreme 3.38
3.71
1 month 3.38
Extreme 3.38
4.25
Current year 2.95
Extreme 2.95
5.78
1 year 1.47
Extreme 1.4705
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 2021-03-11
Director of Finance/CFO 44 2026-05-14
Chief Tech/Sci/R&D Officer - 2026-07-19
Director TitleAgeSince
Director/Board Member 68 2021-06-03
Chairman 61 2019-03-31
Director/Board Member 56 2019-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Director

3,694 0.0022%
7/20/26 Free

Chief Technology Officer

137,036 0.0832%
7/7/26 Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
-3.08%-1.14%+112.27%-61.56% 572M
-2.54%+1.31%+55.10%+120.84% 1,135B
-1.42%+3.23%+37.07%+74.26% 636B
+0.16%+0.08%+25.14%+97.36% 505B
-0.31%+3.09%+43.92%+64.55% 378B
-1.34%-0.47%+66.63%+40.56% 358B
-0.68%+2.65%+22.46%+51.48% 295B
-1.20%+3.04%+2.62%+26.97% 266B
-1.79%+1.57%+49.97%+60.87% 237B
-0.73%-0.10%+29.24%+101.19% 193B
Average -1.29%+1.84%+44.44%+57.65% 400.49B
Weighted average by Cap. -1.35%+2.66%+41.00%+82.11%

Financials

2026 *2027 *
Net sales 471M 421M 389M 353M 660M 44.76B 670M 4.68B 1.85B 23.42B 1.77B 1.73B 73.93B 494M 441M 407M 369M 692M 46.91B 702M 4.9B 1.94B 24.55B 1.85B 1.81B 77.47B
Net income 203M 181M 168M 152M 285M 19.3B 289M 2.02B 798M 10.1B 763M 747M 31.88B 220M 196M 181M 164M 308M 20.87B 313M 2.18B 863M 10.92B 825M 807M 34.48B
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
26-10-23 US$3.460 -3.08% 1,261,258
26-10-22 US$3.570 +0.56% 1,041,159
26-10-21 US$3.550 -2.20% 1,519,126
26-10-20 US$3.630 +1.97% 1,641,394
26-10-19 US$3.560 +1.71% 1,679,093
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.460USD
Average target price
6.100USD
Spread / Average Target
+76.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ironwood Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IRWD Stock